Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial

2015 ◽  
Vol 18 (1) ◽  
pp. 96-99 ◽  
Author(s):  
M. Davies ◽  
T. Sasaki ◽  
J. L. Gross ◽  
G. Bantwal ◽  
Y. Ono ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Detemir ◽  
Insulin Degludec ◽  
Treat To Target ◽  
Target Trial

Metabolic control of insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes†

2012 ◽  
pp. n/a-n/a ◽  
Author(s):  
Revital Nimri ◽  
Yael Lebenthal ◽  
Shlomit Shalitin ◽  
Hadasa Benzaquen ◽  
Sharon Demol ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Metabolic Control ◽  
Insulin Detemir ◽  
Treat To Target ◽  
Basal Bolus

scholarly journals Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

2019 ◽  
Vol 7 (1) ◽  
pp. e000664 ◽  
Author(s):  
Nandu Thalange ◽  
Jens Gundgaard ◽  
Witesh Parekh ◽  
Deniz Tutkunkardas
Keyword(s):  
Type 1 Diabetes ◽  
Cost Analysis ◽  
Children And Adolescents ◽  
Annual Cost ◽  
Insulin Detemir ◽  
Cost Savings ◽  
Insulin Degludec ◽  
Age Group ◽  
The Uk

ObjectiveWith healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value. This study evaluated the annual costs of insulin degludec (degludec) versus insulin detemir (IDet) in children and adolescents with type 1 diabetes (T1D) in the UK.Research design and methodsUsing data from a randomized, treat-to-target, non-inferiority trial—BEGIN YOUNG 1—annual costs with degludec versus IDet in children and adolescents aged 1–17 years with T1D were estimated, as costs of these insulins and hyperglycemia with ketosis events. Analyses by age group (1–5, 6–11 and 12–17 years) and scenario (no ketosis benefit, no dose benefit, hyperglycemia with ketones >0.6 and >3.0 mmol/L and the additional costs of twice-daily IDet in 64% of patients) were also performed.ResultsThe mean annual cost per patient was estimated as £235.16 for degludec vs £382.91 for IDet, resulting in an annual saving of £147.75 per patient. These substantial cost savings were driven by relative reductions in the frequency of hyperglycemia with ketosis and basal insulin dose with degludec versus IDet. Annual savings in favor of degludec were observed across each age group (£122.63, £140.59 and £172.50 for 1–5, 6–11 and 12–17 years age groups, respectively). Five scenario analyses further demonstrated the robustness of the results, which included no ketosis or dose benefits in favor of degludec.ConclusionsDegludec provides appreciable annual cost savings compared with IDet in children and adolescents with T1D in a UK setting. While a cost-effectiveness analysis could incorporate the health impact of treatment complications better than the present cost analysis, the strong generalizability of the data from this study suggests that degludec can help healthcare providers to maximize health outcomes despite increasingly stringent budgets.

Sign in / Sign up

Export Citation Format

Share Document